XXII Congresso Brasileiro de Oncologia Clínica

Dados do Trabalho


Título

EGFR MUTATIONS AND PD-L1 EXPRESSION IN EARLY-STAGE NON–SMALL-CELL LUNG CANCER: REAL-WORLD DATA FROM A SINGLE CENTER IN BRAZIL.

Introdução

Targeted and immunotherapies are currently moving towards early-stage settings for non-small cell lung cancer (NSCLC) patients. Data about predictive biomarkers are scarce in this scenario.

Objetivo

The present study aimed to describe the frequency of EGFR mutations and PD-L1 expression in early-stage non-squamous NSCLC patients from a single Brazilian center.

Método

We retrospectively evaluated a series of NSCLC diagnosed at an early-stage (IB to IIIA – AJCC 7th edition) at a Brazilian cancer center (n=302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized as < 1%, 1-49%, and ≥ 50%. We evaluated the association between EGFR mutational status and PD-L1 expression with sociodemographic and clinicopathological parameters by Fisher’s test, qui-square test, and logistic regression. Survival analysis was assessed by the Kaplan-Meier method and Cox regression model. This is an externally sponsored research (ESR) supported by AstraZeneca do Brasil.

Resultado

EGFR mutations were detected in 17.3% (n=48) of cases, and they were associated with female sex, never smokers, and longer overall and event-free survival. PD-L1 positivity was observed in 36.7% (n=69) of the cases [TPS 1-49% n=44(23.4%); TPS ≥50% n=25(13.3%)]. PD-L1 positivity was associated with smoking, weight loss, and increased disease staging (IIB/IIIA).

Conclusão

In conclusion, in this series of Brazilian early-stage NSCLC patients, the frequency of EGFR mutations was 17.3% and the PD-L1 positivity 36.7% of cases. These results can help the tailored treatment in early-stage NSCLC patients.

Palavras-chave

Lung cancer, Precision Medicine, Biomarkers

Área

Oncologia - Tumores torácicos

Autores

ICARO ALVES PINTO, RODRIGO DE OLIVEIRA CAVAGNA, ALINE LARISSA VIRGINIO DA SILVA1, JOSIANE MOURÃO DIAS, IARA VIDIGAL SANTANA, LAÍSA CAROLINA SOUZA, FLÁVIO AUGUSTO FERREIRA DA SILVA, MARIA FERNANDA BIAZOTTO FERNANDES, GUSTAVO DIX JUNQUEIRA PINTO, IZABELLA SANTOS NEGREIROS, MARIA FERNANDA SANTIAGO GONÇALVES, FLÁVIA ESCREMIM DE PAULA, GUSTAVO NORIZ BERARDINELLI, GIOVANA MARIA STANFOCA CASAGRANDE, MARCELA OLIVEIRA DA SILVA, EDUARDO CAETANO ALBINO DA SILVA, MARCO ANTONIO DE OLIVEIRA, ALEXANDRE JACINTO, VINICIUS DUVAL DA SILVA, RUI MANUEL REIS, PEDRO DE MARCHI, LETICIA FERRO LEAL